Skip to main content

Table 3 Prevalence of Pfmdr1 polymorphisms in pre-treatment and post-treatment samples stratified by treatment arms, therapeutic efficacy monitoring, Mali, 2015–2016

From: Therapeutic efficacy of artemether–lumefantrine and artesunate–amodiaquine for the treatment of uncomplicated Plasmodium falciparum malaria in Mali, 20152016

  AL arm   ASAQ arm  
Pre-treatment n, (%) Post-treatment n, (%) p-value* Pre-treatment n, (%) Post-treatment n, (%) p-value*
Pfmdr1 point mutations
Pfmdr1 codon 86 n = 126 n = 36   n = 120 n = 27  
 N86 103 (81.7) 35 (97.2) 0.1954 97 (80.8) 22 (81.5) 0.767
 86N/Y 9 (7.1) 0 (0.0)   5 (4.2) 2 (7.4)  
 86Y 14 (11.1) 1 (2.8)   18 (15.0) 3 (11.1)  
Pfmdr1 codon 184 n = 144 n = 36   n = 140 n = 26  
 Y184 44 (30.6) 7 (19.4) 0.1029 38 (27.1) 5 (19.2) 0.464
 184Y/F 19 (13.2) 0 (0.0)   15 (10.7) 3 (11.5)  
 184F 81 (56.3) 29 (80.6)   87 (62.1) 18 (69.2)  
Pfmdr1 codon 1246 n = 152 n = 39   n = 146 n = 25  
 D1246 149 (98.0) 39 (100.0) 1 144 (98.6) 24 (96.0) 1
 1246D/Y 0 (0.0) 0 (0.0)   0 (0.0) 1 (4.0)  
 1246Y 3 (2.0) 0 (0.0)   2 (1.4) 0 (0.0)  
Pfmdr1 haplotypes n = 124 n = 35   n = 115 n = 24  
 NFD 74 (59.7) 27 (77.1)* 0.014 71 (61.7) 17 (70.8) 1
 NYD 56 (45.2) 7 (20.0)   39 (33.9) 6 (25.0)  
 YFD 20 (16.1) 1 (2.9)   19 (16.5) 4 (16.7)  
 NFY 0 (0.0) 0 (0.0)   0 (0.0) 1 (4.2)  
 NYY 0 (0.0) 0 (0.0)   0 (0.0) 1 (4.2)  
 YYD 4 (3.2) 0 (0.0)   2 (1.7) 1 (4.2)  
YFY 1 (0.8) 0 (0.0)   0 (0.0) 1 (4.2)  
 YYY 2 (1.6) 0 (0.0)   2 (1.7) 1 (4.2)  
  1. Bold letter denotes an encoded amino acid change
  2. Haplotypes defined at codons 86, 184, and 1246; haplotype numerators include isolates with mixed infections
  3. *Comparing wild-type vs. mutant (excluding mixed infections) for point mutations and NFD versus sum of non-NFD for haplotypes